xc
like i mentioned earlier . not competing with ssh or with lvads. our main focus is grade 3 hf with a portion of grade 4 . so far our competition for grade 3 hf is no one. hence , the addressing the market and cardiologists and patients that they are indeed sick and in need of a solution rather than doing nothing and letting their condition deteriorate.
concerning lvads , if cpulse proves its efficiency , it will spell trouble to lvads as we will take a portion of their market share. more affordable less invasive less risk no blood contact + cpulse 2 on the way ?
happy with the structure of the company , I feel dave has done a remarkable job on all fronts . financing , appointments , media presence .
the share price doesnt reflect the great work the company has been making.
lots of potential milestones coming up hopefully
- higher enrollments
- german reimbursement
- euro distribution deal ?
- fda interim analysis approval
- buyout rumors edwards ?
- cpulse 2 first human implant ?
all the best
- Forums
- ASX - By Stock
- SHC
- Oh dear !!
Oh dear !!, page-43
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SHC (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online